OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.
OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.
复制标题
DOI：
10.1111/j.1600-065x.2011.01062.x
复制
发表时间：
2011-11
影响因子：
8.7
通讯作者：
Salek-Ardakani S
中科院分区：
文献类型：
--
作者：
Goulding J;Tahiliani V;Salek-Ardakani S
人类呼吸道是200多种已知病毒的入口，这些病毒共同导致全球每年数百万人死亡。因此，世界卫生组织已将呼吸道病毒感染指定为疫苗开发的优先事项。尽管在理解保护性粘膜抗病毒免疫应答的属性方面取得了巨大进展，但目前的疫苗仍然无法有效产生长期保护性CD8+ T细胞免疫。迄今为止，大多数许可的人用疫苗通过产生特异性免疫球蛋白应答来提供针对感染性病原体的保护。近年来，对特异性共刺激通路的选择性操纵引起了越来越多的关注，这些共刺激通路在调节T细胞介导的免疫应答中至关重要。动物模型中令人印象深刻的结果表明，肿瘤坏死因子受体（TNFR）家族成员OX40（CD134）及其结合配偶体OX40L（CD252）是参与在粘膜表面（如肺）产生保护性CD8+ T细胞应答的关键共刺激分子。在这篇综述中，我们强调了这些新发现，特别强调了它们作为免疫佐剂增强痘病毒CD8+ T细胞疫苗的潜力。
Summary: The human respiratory tract is an entry point for over 200 known viruses that collectively contribute to millions of annual deaths worldwide. Consequently, the World Health Organization has designated respiratory viral infections as a priority for vaccine development. Despite enormous advances in understanding the attributes of a protective mucosal antiviral immune response, current vaccines continue to fail in effectively generating long‐lived protective CD8+ T‐cell immunity. To date, the majority of licensed human vaccines afford protection against infectious pathogens through the generation of specific immunoglobulin responses. In recent years, the selective manipulation of specific costimulatory pathways, which are critical in regulating T cell‐mediated immune responses, has generated increasing interest. Impressive results in animal models have shown that the tumor necrosis factor receptor (TNFR) family member OX40 (CD134) and its binding partner OX40L (CD252) are key costimulatory molecules involved in the generation of protective CD8+ T‐cell responses at mucosal surfaces, such as the lung. In this review, we highlight these new findings with a particular emphasis on their potential as immunological adjuvants to enhance poxvirus‐based CD8+ T‐cell vaccines.